Disease · EFO_1000714
impetigo
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. impetigo. Diseases, record EFO_1000714. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1000714
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs8
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RETAPAMULIN | CHEMBL1658 | Small molecule | Approval | DailyMed and TTD | 12 | 7 | 7 | Drugs and targets |
| MUPIROCIN | CHEMBL719 | Small molecule | Approval | DailyMed | 9 | 6 | 6 | Drugs and targets |
| OZENOXACIN | CHEMBL3990047 | Small molecule | Approval | FDA and TTD | 5 | 2 | 2 | Drugs and targets |
| LINEZOLID | CHEMBL126 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AURICLOSENE | CHEMBL1207907 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LTX-109 | CHEMBL1817968 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MINOCYCLINE | CHEMBL1434 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FUSIDIC ACID | CHEMBL374975 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets0
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
None in this release.
Trials15
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00626795 | Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL) | Phase 2 | 773 | 2018-07-23 | Impetigo, Secondarily Infected Traumatic Lesions | MUPIROCIN | Its record names the disease | ClinicalTrials.gov |
| NCT01397461 | Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo | Phase 3 | 465 | 2016-05-18 | Impetigo | OZENOXACIN, RETAPAMULIN | Its record names the disease | ClinicalTrials.gov |
| NCT02090764 | Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo | Phase 3 | 412 | 2016-05-19 | Impetigo | OZENOXACIN | Its record names the disease | ClinicalTrials.gov |
| NCT00852540 | Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA | Phase 3 | 410 | 2011-08-26 | Skin Infections, Bacterial | LINEZOLID, RETAPAMULIN | Its record names the disease | ClinicalTrials.gov |
| NCT00555061 | Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections. | Phase 4 | 60 | 2010-04-30 | Skin Infections, Bacterial | RETAPAMULIN | Its record names the disease | ClinicalTrials.gov |
| NCT00133874 | Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo | Phase 3 | 520 | Skin Infections, Bacterial | RETAPAMULIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04287777 | Safety and Efficacy of Mupirocin Gel in Children With Impetigo | Phase 3 | 467 | Impetigo | MUPIROCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00133848 | Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment | Phase 3 | 210 | Impetigo | RETAPAMULIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01803035 | A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo | Phase 2 | 210 | Non-bullous Impetigo | LTX-109 | Its record names the disease | ClinicalTrials.gov | |
| NCT01367314 | Safety and Efficacy of Topical NVC-422 Gel in Impetigo | Phase 2 | 129 | Impetigo | AURICLOSENE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 15
See all 15 trialsComparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ozenoxacin vs Placebo: serious adverse events | 0 of 206 | 0 of 205 | 411 | NCT02090764 | Trial comparisons |
| Retapamulin Ointment, 1% (Weight/Weight) Plus Oral Placebo vs Linezolid Plus Placebo Ointment: Number of Participants With Clinical Response at Follow-up | 161 of 268 | 112 of 136 | 404 | NCT00852540 | Trial comparisons |
| Retapamulin Ointment, 1% (Weight/Weight) Plus Oral Placebo vs Linezolid Plus Placebo Ointment: serious adverse events | 3 of 267 | 3 of 137 | 404 | NCT00852540 | Trial comparisons |
| Retapamulin Ointment, 1% (Weight/Weight) Plus Oral Placebo vs Linezolid Plus Placebo Ointment: Number of Participants With Therapeutic Response at Follow-up | 100 of 177 | 65 of 78 | 255 | NCT00852540 | Trial comparisons |
Retapamulin Ointment, 1% (Weight/Weight) Plus Oral Placebo vs Linezolid Plus Placebo Ointment: Number of Participants Who Achieved Microbiological Response (MR) at Follow-up (FU) Who Had a Baseline Pathogen (BP) | 100 of 177 | 65 of 78 | 255 | NCT00852540 | Trial comparisons |
Retapamulin Ointment, 1% (Weight/Weight) Plus Oral Placebo vs Linezolid Plus Placebo Ointment: Number of Participants Achieving Microbiological Response (MR) at Follow-up (FU) Who Had MRSA as a Baseline Pathogen (BP) | 41 of 72 | 32 of 38 | 110 | NCT00852540 | Trial comparisons |
Retapamulin Ointment, 1% (Weight/Weight) Plus Oral Placebo vs Linezolid Plus Placebo Ointment: Number of Participants Achieving Clinical Response at Follow-up Who Had Methicillin-resistant Staphlococcus Aureus (MRSA) as a Baseline Pathogen | 41 of 72 | 32 of 38 | 110 | NCT00852540 | Trial comparisons |
Papers from its trials3
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_1000714
GET https://conductscience.org/api/diseases/v1/EFO_1000714/drugs